Seaward Management Limited Partnership decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 210,354 shares of the biopharmaceutical company’s stock after selling 7,909 shares during the quarter. Seaward Management Limited Partnership’s holdings in Gilead Sciences were worth $17,042,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of GILD. Sanders Capital LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $427,585,000. Renaissance Technologies LLC grew its position in shares of Gilead Sciences by 35.0% in the 2nd quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after acquiring an additional 2,700,600 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Gilead Sciences by 84.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,505,708 shares of the biopharmaceutical company’s stock valued at $446,197,000 after purchasing an additional 2,524,657 shares during the period. Vanguard Group Inc. boosted its position in Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in Gilead Sciences by 50.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock valued at $438,244,000 after purchasing an additional 2,062,886 shares during the period. Institutional investors own 75.95% of the company’s stock.
In other news, EVP James R. Meyers sold 100,000 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total value of $8,024,000.00. Following the sale, the executive vice president now owns 102,715 shares of the company’s stock, valued at approximately $8,241,851.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold a total of 591,666 shares of company stock worth $44,466,567 in the last three months. Company insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $81.17 on Friday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The firm has a market capitalization of $106,000.00, a price-to-earnings ratio of 9.23, a price-to-earnings-growth ratio of -1.77 and a beta of 1.13. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.75 EPS. equities research analysts expect that Gilead Sciences, Inc. will post 8.48 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.66%.
GILD has been the subject of a number of analyst reports. Berenberg Bank set a $96.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Credit Suisse Group restated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, December 7th. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. Finally, Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price objective for the company in a research report on Friday, October 13th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eighteen have given a buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and a consensus price target of $85.53.
TRADEMARK VIOLATION NOTICE: “Seaward Management Limited Partnership Decreases Stake in Gilead Sciences, Inc. (GILD)” was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.truebluetribune.com/2018/01/19/seaward-management-limited-partnership-decreases-stake-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.